Residency · Residency · Vascular Surgery

Deep Venous Thrombosis: Diagnosis, Anticoagulation, and Thrombus Removal

Overview

Deep venous thrombosis (DVT) is a common vascular emergency that affects approximately 1 to 2 adults per 1,000 annually. It is part of the broader venous thromboembolism (VTE) spectrum, which also includes pulmonary embolism (PE). The major complications of DVT include PE, which can be fatal, post-thrombotic syndrome (PTS), and recurrent VTE. Treatment strategies have evolved over time, moving from traditional heparin and warfarin therapy to direct oral anticoagulants (DOACs). However, there remains ongoing debate regarding the role of thrombus removal in management.

Risk Factors and Virchow's Triad

DVT risk factors are classically explained by Virchow's triad, which includes stasis, endothelial injury, and hypercoagulability.

Stasis

Venous stasis occurs with immobilization, prolonged travel, paralysis, or extended bed rest. It is also common after cast immobilization or in the post-surgical state. Venous compression syndromes, such as May-Thurner syndrome, tumors, or pregnancy-related compression, contribute to stasis by obstructing venous flow.

Endothelial Injury

Endothelial injury can result from surgery, trauma, or the presence of central venous catheters. A history of prior DVT or varicose veins also predisposes to endothelial damage. Chemical injury from intravenous drug use or chemotherapy can further injure the venous endothelium.

Hypercoagulability

Hypercoagulability can be inherited or acquired. Inherited causes include Factor V Leiden mutation, which is the most common, prothrombin G20210A mutation, and deficiencies of protein C, protein S, or antithrombin III. Acquired hypercoagulable states include malignancy, use of oral contraceptives or hormone replacement therapy, pregnancy, antiphospholipid syndrome, myeloproliferative disorders, nephrotic syndrome, and heparin-induced thrombocytopenia (HIT). When multiple risk factors coexist, their effects are synergistic, greatly increasing the risk of thrombosis.

Diagnosis

Clinical Presentation

Patients with DVT typically present with unilateral leg swelling, pain, warmth, and erythema. The Homan sign, which is calf pain elicited by dorsiflexion of the foot, is unreliable as it lacks both sensitivity and specificity. Severe forms include phlegmasia alba dolens, characterized by a massive iliofemoral DVT causing a painful, white, swollen leg, and phlegmasia cerulea dolens, which carries a risk of venous gangrene due to elevated compartment pressures and represents a surgical emergency.

Wells Score for DVT

The Wells score is a clinical prediction rule that combines risk factors and physical signs to estimate the probability of DVT. A score of 2 or higher indicates that DVT is likely, warranting duplex ultrasound imaging. A score below 2 suggests DVT is unlikely, and in these cases, a D-dimer test is performed; a negative D-dimer effectively excludes DVT. The Wells score includes factors such as active cancer, paralysis or immobilization, bedridden status for more than three days or recent surgery within 12 weeks, tenderness along deep veins, entire leg swelling, calf swelling greater than 3 cm compared to the contralateral leg, pitting edema, collateral superficial veins, and subtracts points if an alternative diagnosis is more likely.

D-Dimer

D-dimer testing has high sensitivity (95-97%) but low specificity (40-50%) for DVT. It is most useful to exclude DVT in patients with low clinical probability due to its high negative predictive value. However, D-dimer levels can be elevated in various conditions such as pregnancy, malignancy, infection, post-surgical states, advanced age, and trauma. Using an age-adjusted D-dimer cutoff (age multiplied by 10 µg/L for patients over 50 years) improves specificity without compromising sensitivity.

Duplex Ultrasound

Duplex ultrasound is the gold standard for diagnosing DVT, with sensitivity exceeding 95% for proximal DVT. The key diagnostic feature is the inability to fully compress the vein during compression ultrasonography, indicating the presence of thrombus. Augmentation maneuvers and color flow Doppler help assess venous flow patterns. Ultrasound is less sensitive for isolated calf DVT (70-80%) and iliac vein thrombosis. If the initial ultrasound is negative but clinical suspicion remains high, a repeat scan in 5 to 7 days is recommended.

Additional Imaging

CT venography is useful for detecting iliac or pelvic DVT that is not well visualized on ultrasound. MR venography serves as an alternative imaging modality in pregnancy or in patients with contrast allergies. Contrast venography, once considered the diagnostic gold standard, is now rarely used. Intravascular ultrasound (IVUS) is primarily used intraoperatively to assess iliac vein pathology such as stenosis or compression.

<image>Duplex ultrasound images demonstrating a normal compressible common femoral vein versus non-compressible vein with intraluminal echogenic thrombus diagnostic of DVT</image>

Anticoagulation

Initial Treatment

Unfractionated heparin (UFH) is administered as an intravenous bolus of 80 units per kilogram followed by an infusion of 18 units per kilogram per hour, titrated to achieve an activated partial thromboplastin time (aPTT) 1.5 to 2.5 times the control. UFH is preferred when invasive procedures are anticipated due to its short half-life and reversibility with protamine. It is also indicated in massive DVT, renal failure, or situations with high bleeding risk.

Low-molecular-weight heparin (LMWH), such as enoxaparin at 1 mg/kg twice daily or 1.5 mg/kg once daily, allows for outpatient treatment of uncomplicated DVT. LMWH has predictable pharmacokinetics and generally does not require routine monitoring, except in cases of obesity or renal impairment where anti-Xa levels may be checked. LMWH is preferred for cancer-associated DVT.

Fondaparinux, dosed at 7.5 mg daily (adjusted to 5 mg if under 50 kg and 10 mg if over 100 kg), is an alternative anticoagulant in patients with HIT due to its lack of cross-reactivity.

Rivaroxaban and apixaban can be used as initial monotherapy without the need for a heparin lead-in phase.

Long-Term Anticoagulation

Direct oral anticoagulants (DOACs) are preferred for non-cancer-related DVT. Rivaroxaban is given as 15 mg twice daily for 21 days followed by 20 mg once daily. Apixaban is dosed at 10 mg twice daily for 7 days, then 5 mg twice daily. Edoxaban and dabigatran require at least 5 days of parenteral anticoagulation before initiation, with edoxaban dosed at 60 mg daily and dabigatran at 150 mg twice daily.

Warfarin remains in use for patients with antiphospholipid syndrome, severe renal impairment, or mechanical heart valves. It requires overlap with heparin for at least five days and until the international normalized ratio (INR) is 2.0 or greater for 24 hours.

LMWH remains the preferred agent for cancer-associated VTE, as demonstrated by the CLOT trial, although DOACs are increasingly used based on recent trials such as SELECT-D and Hokusai VTE Cancer.

Duration of Anticoagulation

For provoked DVT, such as those related to surgery, trauma, or immobilization, anticoagulation is typically continued for three months. Unprovoked DVT warrants a minimum of three months of therapy followed by reassessment to determine the need for extended anticoagulation. Patients with recurrent unprovoked VTE generally require indefinite anticoagulation. In cancer-associated DVT, anticoagulation is continued as long as the cancer is active or the patient is undergoing treatment.

The decision to extend anticoagulation balances the risk of VTE recurrence against bleeding risk, often guided by adapted bleeding risk scores like HAS-BLED. Reduced-dose extended therapy with rivaroxaban (10 mg daily) or apixaban (2.5 mg twice daily) after initial treatment has been shown to reduce recurrence with a lower risk of bleeding.

<image>Algorithm for DVT diagnosis and initial management showing Wells score stratification, D-dimer testing pathway, duplex ultrasound confirmation, and anticoagulation selection</image>

Thrombus Removal Strategies

Catheter-Directed Thrombolysis (CDT)

Catheter-directed thrombolysis involves the infusion of a thrombolytic agent, such as alteplase (tPA), directly into the thrombus via a catheter. The typical protocol administers tPA at 0.5 to 1.0 mg per hour with concurrent heparin infusion for 12 to 48 hours. This approach requires intensive care unit monitoring, serial fibrinogen measurements, and repeat venography to assess treatment progress. CDT yields the best results when initiated within 14 days of symptom onset, targeting acute thrombus. It is primarily indicated for iliofemoral DVT in young, active patients to prevent post-thrombotic syndrome.

Pharmacomechanical Thrombectomy (PMT)

Pharmacomechanical thrombectomy combines mechanical clot disruption or aspiration with thrombolytic infusion. Devices used include AngioJet (rheolytic), EKOS (ultrasound-accelerated CDT), ClotTriever, and FlowTriever. These methods offer potential advantages such as shorter treatment times, reduced thrombolytic doses, and the possibility of a single-procedure approach. The EKOS system uses ultrasound waves to separate fibrin strands, enhancing tPA penetration into the thrombus.

Surgical Thrombectomy

Surgical thrombectomy is rarely performed for DVT and is reserved for severe cases such as phlegmasia cerulea dolens with limb-threatening ischemia. The procedure involves venous thrombectomy via venotomy with balloon catheter extraction of the thrombus. Sometimes, an arteriovenous fistula is created to maintain venous patency. Fasciotomy is often necessary due to the risk of compartment syndrome.

ATTRACT Trial

The ATTRACT trial was a multicenter randomized controlled trial comparing CDT/PMT plus anticoagulation versus anticoagulation alone for proximal DVT. The primary outcome showed no significant reduction in post-thrombotic syndrome at 24 months (47% vs. 48%). Secondary findings indicated that CDT/PMT reduced moderate-to-severe PTS and improved acute symptom relief in the iliofemoral DVT subgroup. However, major bleeding was higher with CDT/PMT (1.7% vs. 0.3%). The trial's impact has tempered enthusiasm for routine thrombus removal, though selective use for iliofemoral DVT remains reasonable.

Current Indications for Thrombus Removal

Thrombus removal is strongly indicated in phlegmasia cerulea dolens due to limb-threatening venous congestion. It is also considered for acute iliofemoral DVT in young, active patients with low bleeding risk and good functional status, especially when symptoms are less than 14 days in duration, as acute thrombus is more responsive to lysis. Thrombus removal is not recommended for femoropopliteal or isolated calf DVT.

Post-Thrombotic Syndrome (PTS)

Pathophysiology

PTS arises from thrombus organization and incomplete recanalization, which damage venous valves. Persistent venous obstruction combined with valvular reflux leads to chronic venous hypertension. This syndrome develops in 20 to 50% of patients with proximal DVT within two years.

Diagnosis

The Villalta score is used to diagnose and grade PTS by scoring clinical signs and symptoms such as pain, cramps, heaviness, pruritus, paresthesias, edema, skin induration, hyperpigmentation, redness, pain during calf compression, and venous ulcers. Scores of 5 to 9 indicate mild PTS, 10 to 14 moderate, and 15 or higher or the presence of ulcers signify severe PTS.

Prevention

Adequate anticoagulation is essential to prevent recurrent DVT and subsequent PTS. Elastic compression stockings were previously recommended based on the Brandjes trial; however, the SOX trial demonstrated no benefit in preventing PTS with routine two-year compression stocking use. Current practice favors compression stockings primarily for symptom relief rather than prevention. Early mobilization is encouraged, as bed rest does not prevent PE and may worsen outcomes.

Treatment

Management of PTS includes compression therapy for symptom control and exercise rehabilitation. Iliac vein stenting may be considered for post-thrombotic obstruction (see Topic 38). Deep venous valve reconstruction is an option in specialized centers but has limited evidence.

<image>Venogram images showing acute iliofemoral DVT before and after catheter-directed thrombolysis with restored venous patency and identification of underlying iliac vein compression</image>

Special Situations

Calf Vein (Distal) DVT

Calf vein DVT carries a lower risk of PE compared to proximal DVT. Management options include anticoagulation for three months or serial ultrasound surveillance at 1 to 2 weeks. Anticoagulation is recommended if the patient is symptomatic, has a positive D-dimer, thrombus close to the popliteal vein, no reversible risk factors, cancer, prior VTE, or is an inpatient.

Upper Extremity DVT

Upper extremity DVT can be primary, such as effort thrombosis (Paget-Schroetter syndrome), or secondary due to catheter-related thrombosis, cancer, or pacemaker leads. Treatment involves anticoagulation with or without thrombolysis for primary cases and anticoagulation plus consideration of catheter removal for secondary cases.

DVT in Pregnancy

Low-molecular-weight heparin is the anticoagulant of choice in pregnancy because warfarin is teratogenic and DOACs are contraindicated. Diagnosis relies on duplex ultrasound; if proximal DVT is excluded but suspicion remains, MR venography can be used to evaluate for iliac DVT. Anticoagulation should continue for at least six weeks postpartum, with a minimum total duration of three months.

Cancer-Associated DVT

LMWH has historically been preferred for cancer-associated DVT as demonstrated in the CLOT trial. Recent trials show that DOACs such as edoxaban and rivaroxaban are non-inferior but carry a higher risk of gastrointestinal bleeding in patients with GI or genitourinary cancers. Apixaban may have a lower bleeding risk as shown in the Caravaggio trial. Anticoagulation should continue while cancer is active or the patient is receiving treatment.

Clinical Pearls

A negative D-dimer test in a patient with low clinical probability effectively rules out DVT, and in such cases, ultrasound is not necessary. Conversely, in patients with high clinical probability, D-dimer testing is not recommended; these patients should proceed directly to ultrasound. Bilateral leg swelling is rarely due to DVT and should prompt consideration of other diagnoses such as inferior vena cava thrombosis, heart failure, nephrotic syndrome, or liver disease. May-Thurner syndrome should always be considered in young patients, especially females, presenting with left-sided iliofemoral DVT. Phlegmasia cerulea dolens is a surgical emergency where anticoagulation alone is insufficient; urgent thrombectomy or thrombolysis should be considered. Following the ATTRACT trial, routine catheter-directed thrombolysis for all proximal DVT is not supported, but selective use for iliofemoral DVT in low-risk patients remains reasonable. Extended-dose anticoagulation with apixaban 2.5 mg twice daily or rivaroxaban 10 mg daily after initial treatment significantly reduces recurrence with minimal increase in bleeding risk, as demonstrated in the AMPLIFY-EXT and EINSTEIN-CHOICE trials.

References

• Kearon C, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352.
• Vedantham S, et al. (ATTRACT trial) Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med. 2017;377(23):2240-2252.
• Kahn SR, et al. (SOX trial) Compression stockings to prevent post-thrombotic syndrome. Lancet. 2014;383(9920):880-888.
• Raskob GE, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615-624.
• Agnelli G, et al. (Caravaggio trial) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599-1607.

Read this lecture as Markdown